12th ESO-ESMO Masterclass in Clinical Oncology

30 ESCO credits

16.03.2013 - 21.03.2013

Ermatingen, Switzerland

MASTERCLASS

Description

Chairs: N. Pavlidis, GR - R.A. Stahel, CH
Scientific Co-ordinators: W. Gatzemeier, IT - R. Popescu, CH

AIMS AND OBJECTIVES
This clinically oriented educational programme has been designed for medical or clinical oncologists who wish to improve their skills or those who are preparing for the national board exam. The programme will expose participants to a full spectrum of issues in clinical oncology and to practice-oriented training. The programme focuses on breast, gastro-intestinal, genitourinary, gynaecological, head and neck and lung cancers.
Spotlight sessions will facilitate compact update on haematological diseases, supportive care, treatment of melanoma, radiology for oncology, bone health and cancer, cancer of unknown primary, biology of cancer, oral therapy, pain control, survivorship and side effects and rare cancers.

TEACHING FORMAT
The Masterclass offers plenary lectures regarding state-of-the-art clinical evaluation and treatments with reference to clinical guidelines which will conclude in take-home messages. The Clinical Sessions will be complemented by Tumour Board discussions. Furthermore, participants will deliver case presentations within small groups and discuss these with the chairmen and the faculty.
All participants will reside at the course venue and participation is compulsory throughout the course. The Masterclass will be entirely in English and fluency in English is necessary for admission. Participants of the concomitant Masterclass in Nursing Oncology will attend selected medical sessions whilst the oral cancer therapy, pain control, Survivorship and “new” oncological emergencies sessions will be attended jointly.

THE MASTERCLASS IS:
• A 5-day residential educational event
• Full immersion
• Clinically-oriented
• Multidisciplinary
• An international faculty of top experts delivering lectures focusing on genito-urinary, breast, gynaecological, head and neck, gastro-intestinal and lung cancers.

The Masterclass in Clinical Oncology is an ESO-ESMO joint event


The Masterclass is held in collaboration with the Flims Alumni Club


The 2013 Masterclass is part of the Masterclass-Online Study Program in Advanced Oncology of the University of Ulm

General information

ORGANISING SECRETARIAT
Francesca Marangoni
European School of Oncology
Via del Bollo, 4
20123 Milan, Italy
Ph: +39 02 85464525
Fax: +39 02 85464545
Email: fmarangoni@eso.net

ACCREDITATION
The Accreditation Council for Oncology in Europe (ACOE) has recommended that the event be granted 27 European Continuing Medical Education Credits (ECMEC). The ECMEC will be recognised within the different European States which have agreed to participate in this European system, and by the American Medical Association (AMA) as AMA Pra Category 1 Credits.
The event has also been accredited with 25 ESMO-MORA cat. 1 points.

ACKNOWLEDGEMENTS
ESO wishes to express its appreciation to Wolfsberg Centre for its consideration and support to the 2013 Masterclass.

The Masterclass is part of the Sharing Progress in Cancer Care programme whose sustaining members are:

- Platinum members: Amgen and Eisai
- Gold members: Eli Lilly, GlaxoSmithKline Oncology, Helsinn, Merck Serono, Novartis Oncology and Roche
- Silver members: Boehringer Ingelheim, Celgene Corporation, Genomic Health and Sanofi Oncology

Faculty list

FACULTY (as of January 2013)
M. Aapro, IMO - Clinique de Genolier, Department of Oncology, Genolier, CH
N. Aaronson, Antoni van Leeuwenhoek Hospital, Department of Psychosocial Research and Epidemiology, Amsterdam, NL
J. Bernier, Genolier Swiss Medical Network, Department of Radiotherapy, Genolier, CH
P. Casali, National Cancer Institute, Department of Medical Oncology, Milan, IT
A. Cervantes, Hospital Clinico Universitario, Hematology And Medical Oncology Department, Valencia, ES
A. Dietz, University of Leipzig, Department of Otolaryngology, Leipzig, DE
T. Eisen, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK
C. Faivre-Finn, Christie Hospital NHS Foundation Trust, Department of Clinical Oncology, Manchester, UK
K. Fizazi, Institut Gustave Roussy, Department of Medicine, Villejuif, FR
S.D. Fosså, Univesirsity of Oslo - Institute of Clinical Medicine, Oslo, NO
M. Garassino, National Cancer Institute, Department of Medical Oncology, Milan, IT
W. Gatzemeier, Humanitas Clinical Institute, Breast Unit, Rozzano, IT
M. Ghielmini, Oncology Institute of Southern Switzerland, Division of Medical Oncology, Bellinzona, CH
N. Harbeck, Klinikum Grosshadern, Breast Centre of Munich University, Munich, DE
A. Horwich, The Royal Marsden Hospital, Department of Radiotherapy, Sutton, UK
R. Huddart, The Institute of Cancer Research (ICR) – Royal Marsden Hospital, Sutton Surrey, UK
C.H. Köhne, Klinikum Oldenburg, Klinik für Onkologie / Hämatologie, Oldenburg, DE
P. Lorigan, University of Manchester, Institute of Cancer Sciences, Manchester, UK
D. Lüftner, Charité Hospital, Dept. of Oncology Haematology, Berlin, DE
O. Pagani, Oncology Institute of Southern Switzerland (IOSI), Department
N. Pavlidis, University of Ioannina, Division of Medical Oncology, Ioannina, GR
S. Peters, Centre Hospitalier Universitaire Vaudois, Lausanne Cancer Center, Lausanne, CH
R. Popescu, Hirslanden Clinic, Tumor Center, Department of Medical Oncology, Aarau, CH
K. Redmond, Cancer World Magazine, Lugano, CH
D. Schrijvers, Ziekenhuisnetwerk Antwerpen-Middelheim, Department of Haemato-Oncology, Antwerp, BE
D. Sebag-Montefiore, University of Leeds, Leeds Cancer Centre, Department of Clinical Oncology, Leeds, UK
C. Sessa, Oncology Institute of Southern Switzerland, Division of Medical Oncology, Bellinzona, CH
R.A. Stahel, University Hospital Zurich, Clinic and Policlinic for Oncology, Zurich, CH
F. Strasser, Cantonal Hospital, Department Internal Medicine & Palliative Care Centre, St. Gallen, CH
N. Tunariu, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK
J.B. Vermorken, University Hospital Antwerp, Department of Oncology, Edegem, BE
G. Viale, European Institute of Oncology, Department of Pathology, and Milan University, Milan, IT
W. Weder, University Hospital Zurich, Division of Thoracic Surgery, Zurich, CH

Programme

16 March

	Participants' arrival, airport transfers, registration
14:30	Clinical session Genito-urinary cancers I Chair: K. Fizazi, FR
	Prostate cancer: Local therapy: Surgery and radiotherapy A. Horwich, UK First-line endocrine treatment A. Horwich, UK Endocrine resistant - refractory K. Fizazi, FR
16:10	Clinical session Genito-urinary cancers II Chair: K. Fizazi, FR
	Bladder cancer: Neoadjuvant and adjuvant chemotherapy (locally advanced disease) R. Huddart, UK Metastatic disease: Systemic treatment R. Huddart, UK Renal cancer: Metastatic renal cancer: Evidence-based treatment T. Eisen, UK
17:50	Coffee break
18:20	Tumour board Genito-urinary cancers K. Fizazi, FR - A. Horwich, UK - R. Huddart, UK - T. Eisen, UK
20:30	*Dinner*

17 March

8:30	Clinical session Gastro-intestinal tumours I Chair: D. Sebag-Montefiore, UK
	Colon cancer: Adjuvant and neoadjuvant treatment of colorectal cancer A. Cervantes, ES Systemic treatment in advanced disease C.H. Köhne, DE
10:00	*Coffee break*
10:30	Clinical session Gastro-intestinal tumours II Chair: A. Cervantes, ES
	Management of rectal cancer (surgery and radiotherapy) D. Sebag-Montefiore, UK Systemic treatment in early and advanced gastric cancer A. Cervantes, ES
12:00	Tumour board Gastro-intestinal tumours A. Cervantes, ES - D. Sebag-Montefiore, UK - C.H. Köhne, DE
13:00	Sponsored lecture Management of senior adults with prostate cancer (SPCC lecture by Sanofi) M. Aapro, CH
13:30	Lunch
14:30	Spotlight session 1 Haematological diseases - focus on lymphomas M. Ghielmini, CH
15:15	Spotlight session 2 Supportive care
	Prevention of febrile neutropenia M. Aapro, CH Antiemetics M. Aapro, CH
16:00	*Coffee break*
16:30	Case presentations by participants
18:00	Sponsored lecture Cancer Cachexia Syndrome: Mechanism based clinical approach to achieve reasonable outcomes (SPCC lecture by Helsinn) F. Strasser, CH
19:30	*Dinner*

18 March

8:30	Clinical session Breast cancer I Chair: G. Viale, IT
	What the clinician needs to know about breast pathology G. Viale, IT (Neo)Adjuvant chemotherapy and biological agents N. Harbeck, DE (Neo)Adjuvant endocrine therapy O. Pagani, CH Current controversies and challenges in breast surgery W. Gatzemeier, IT
10:15	*Coffee break*
10:45	Clinical session Breast cancer II Chair: G. Viale, IT
	Management of HER-2+ and triple negative advanced breast cancer N. Harbeck, DE Management of ER+ advanced breast cancer O. Pagani, CH Standards and new techniques in breast radiotherapy J. Bernier, CH
12:15	Tumour board Breast cancer G. Viale, IT - J. Bernier, CH - O. Pagani, CH - N. Harbeck, DE - W. Gatzemeier, IT
13:15	*Lunch*
14:30	Spotlight session 3 Advances in systemic treatment of melanoma P. Lorigan, UK
15:15	Case presetation by participants
16:45	*Coffee break*
15:00	Tumour board Head and neck cancer J.B. Vermorken, BE - A. Dietz, DE - C. Sessa, CH
17:15	Spotlight session 4 Essentials in imaging radiology for oncologists Tunariu, UK
17:45	Spotlight session 5 Bone health and cancer S. Peters, CH
18:15	Spotlight session 6 Cancer of unknown primary N. Pavlidis, GR
19:30	*Dinner*

19 March

8:30	Clinical session Gynaecological cancers Chair: J.B. Vermorken, BE
	Ovarian cancer J.B. Vermorken, BE Cervical and endometrial cancers C. Sessa, CH
10:30	Coffee break
11:00	Clinical session Head and neck cancer Chair: J. Bernier, CH
	Prognostic factors and surgical approach A. Dietz, DE Radiotherapy J. Bernier, CH Systemic therapy J.B. Vermorken, BE
13:00	*Lunch*
14:30	Tumour board Gynaecological cancers J.B. Vermorken, BE - C. Sessa, CH
15:00	Tumour board Head and neck cancer J. Bernier, CH - A. Dietz, DE - J.B. Vermorken, BE
15:30	Spotlight session 6 Biology of cancer S. Peters, CH
16:00	*Free time*
19:00	*Special evening*

20 March

8:30	Clinical session Lung cancer and mesothelioma I Chair: R. Stahel, CH
	Surgery W. Weder, CH Radiotherapy C. Faivre-Finn, UK Non-small cell lung cancer systemic therapy R.A. Stahel, CH
10:30	*Coffee break*
11:00	Clinical session Lung cancer and mesothelioma II Chair: R.A. Stahel, CH
	Small cell lung cancer C. Faivre-Finn, UK Mesothelioma R.A. Stahel, CH
12:00	Tumour board Lung cancer R.A. Stahel, CH - W. Weder, CH - C. Faivre-Finn, UK
13:00	*Lunch*
14:30	Case presentations by participants
16:00	Sponsored lecture Angiogenesis and anti-angiogenesis in ovarian cancer (SPCC lecture by Amgen) D. Lüftner, DE
16:30	*Coffee break*
17:00	Learning assessment test
18:00	Sponsored lecture European consensus paper on GIST management (SPCC lecture by Novartis) P. Casali, IT
18:30	Sponsored lecture Considerations on maintenance treatment (SPCC lecture by Lilly) M. Garassino, IT
19:30	*Dinner*

21 March

8:30	Spotlight session 7 Rare Cancers P. Casali, IT
9:30	JOINT medics and nursing session I
	Pain control – acute/chronic/breakthrough D. Schrijvers, BE Suvivorship and frequent (patient relevant) late side effects from all treatment modalities N. Aaronson, NL
10:30	Coffee break
11:00	JOINT medics and nursing session II
	“New” oncological emergencies - (new problems arising with the newer drugs) S.D. Fosså, NO Facilitating patient adherence to oral cancer therapies K. Redmond, CH
12:00	*Close*

« Back to "2013"